3-T 乳腺MRI静脉管路相位卷折伪影的识别、分析与解决
研究通过体模实验与400例临床对照(对照组200例、干预组200例),评估双侧轴位3-T乳腺DCE-MRI中静脉管路残留对比剂所致相位卷折伪影。体模中仅在0.4 mmol/mL钆浓度且管路靠近FOV边缘或位于350-450 mm FOV内时产生伪影;临床中将静脉管路胶带固定于患者背部可减少伪影(对照组52.5% vs 干预组22%,P<.005)。
要点
- 静脉管路内残留钆对比剂可在3-T乳腺轴位DCE-MRI产生相位卷折伪影。
- 体模中伪影仅见于0.4 mmol/mL钆浓度、管路靠近FOV边缘或位于350-450 mm FOV内。
- 将静脉管路胶带固定于患者背部使其移出FOV,可减少伪影出现。
核心结论
- 将对比剂静脉管路胶带固定于患者背部、使其在采集时移出FOV,可减少双侧轴位3-T DCE乳腺MRI的相位卷折伪影。
研究设计与样本
- 两部分研究:先进行体模实验,随后经机构审查委员会批准的临床干预评估MRI相位卷折伪影。
- 体模模型使用含钆对比剂浓度0、0.4、0.8、1.2、1.6和2 mmol/mL的液体填充静脉管路,并在乳腺线圈3-T MRI下将模拟静脉管路置于多个FOV内评估伪影产生。
- 临床评估共纳入400例患者(对照组:干预组=200:200),判断将静脉管路胶带固定于患者背部对伪影的影响,乳腺MR图像盲法评估伪影存在与否。
- 使用软件进行统计分析,P值小于.05认为差异有统计学意义。
关键影像表现/征象
- 体模模型中,伪影仅在钆浓度为0.4 mmol/mL且管路靠近FOV边缘或位于350-450 mm FOV内时产生。
- 临床实验中,相位卷折伪影在回顾性对照组比前瞻性干预组更常见(对照组52.5%[200例中105例]vs 干预组22%[200例中44例];P<.005)。
临床应用与阅片要点
- 阅片时若见相位卷折伪影,可考虑其来源于静脉管路内残留对比剂,尤其在管路靠近FOV边缘或位于350-450 mm FOV内时。
- 采集双侧轴位3-T DCE乳腺MRI时,可将对比剂静脉管路胶带固定于患者背部以使其移出FOV,从而减少伪影。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To understand and remove the source of a phase-wrap artifact produced by residual contrast agent in the intravenous line during acquisition of bilateral axial 3-T dynamic contrast material-enhanced (DCE) breast MRI.
MATERIALS AND METHODS: A two-part study involved a phantom experiment, followed by an institutional review board approved clinical intervention, to evaluate the phase-wrap artifact at MRI. A phantom model evaluated artifact production by using an intravenous line filled with fluids with varying concentrations of gadolinium-based contrast agent (0, 0.4, 0.8, 1.2, 1.6, and 2 mmol/mL) and by positioning the simulated intravenous line within several fields of view (FOV) at 3-T MRI in breast coils. Next, a clinical assessment was performed with a total of 400 patients (control group:interventional group, 200:200) to determine the effect of taping the intravenous line to the patients' backs. Breast MR images were assessed blindly for the presence of the artifact. Software was used for statistical analysis with a P value of less than .05 considered a significant difference.
RESULTS: In the phantom model, the artifact was produced only with a 0.4 mmol/mL gadolinium concentration and when the tubing was either close to the edge or within a FOV of 350-450 mm. In the clinical experiment, the artifact was more prevalent in the retrospective control group than in the prospective intervention group (52.5% [105 of 200] vs 22% [44 of 200]; P < .005).
CONCLUSION: The presence of phase-wrap artifacts can be reduced by moving the contrast agent intravenous line out of the FOV during acquisition by taping it to a patient's back during bilateral axial 3-T DCE breast MRI.Keywords: Breast, MR-Imaging, Phantom Studies© RSNA, 2020.
引用
- Slonimsky E, Azraq Y, Gomori JM, et al. Intravenous Line Phase-Wrap Artifact at Bilateral Axial 3-T Breast MRI: Identification, Analysis, and Solution. Radiol Imaging Cancer. 2020. PMID: 33778747. doi:10.1148/rycan.2020200004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。